Keyphrases
C-type Natriuretic Peptide
100%
Antiarrhythmic Effect
100%
Phosphodiesterase 2
100%
Catecholamines
18%
Cyclic GMP
18%
High Dose
9%
Myocardial Infarction
9%
Phosphorylation
9%
Ventricular Arrhythmia
9%
Beneficial Effects
9%
Trigger Mechanism
9%
Signaling Pathway
9%
Arrhythmia
9%
Organ Level
9%
Lethal Complication
9%
Ischemia-reperfusion Injury
9%
Cardioprotection
9%
Sudden Cardiac Death
9%
Mouse in Vivo
9%
Antiarrhythmic Therapy
9%
Ca2+
9%
Cardiomyocytes
9%
Mouse Heart
9%
Arrhythmias Cardiac
9%
Unique Properties
9%
CAMP Signaling
9%
Isolated Cardiomyocytes
9%
CGMP Signaling
9%
2-axis
9%
Ventricular Cardiomyocytes
9%
Spark Frequency
9%
Human Induced Pluripotent Stem Cell-derived Cardiomyocytes (hiPSC-CMs)
9%
IPSC-derived Cardiomyocytes
9%
Ca2+-binding Protein
9%
Antiarrhythmic Strategies
9%
Key Experiments
9%
Biochemistry, Genetics and Molecular Biology
Phosphodiesterase 2
100%
C-Type Natriuretic Peptide
100%
Antiarrhythmic Activity
100%
Cardiac Muscle Cell
45%
Cyclic Adenosine Monophosphate
27%
Cyclic Guanosine Monophosphate
27%
Cardiac Dysrhythmia
18%
Catecholamine
18%
Drug Megadose
9%
Enzymatic Hydrolysis
9%
Reperfusion
9%
Sudden Cardiac Death
9%
Induced Pluripotent Stem Cell
9%
Drug Therapy
9%
Human Induced Pluripotent Stem Cell
9%
INIS
phosphodiesterases
100%
peptides
100%
mice
36%
levels
18%
humans
18%
inhibition
18%
catecholamines
18%
doses
9%
injection
9%
stimulation
9%
myocardial infarction
9%
death
9%
phosphorylation
9%
stem cells
9%
proteins
9%
organs
9%
in vivo
9%
injuries
9%
ischemia
9%
pharmacotherapy
9%
lethals
9%
Pharmacology, Toxicology and Pharmaceutical Science
Phosphodiesterase
100%
Natriuretic Peptide Type C
100%
Antiarrhythmic Drug
100%
Cyclic GMP
27%
Calcium Ion
18%
Catecholamine
18%
Reperfusion Injury
9%
Heart Arrhythmia
9%
Pharmacotherapy
9%
Heart Infarction
9%
Sudden Cardiac Death
9%
Heart Ventricle Arrhythmia
9%